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INTRODUCTION
Chronic kidney disease (CKD) is now seen as a systemic disease
involving also the central nervous system [1], but the link be-
tween the kidney and different organ systems and disease went
unnoticed for a long time. The king of Poland, Stephen Bathory
(1533–86), suffered from CKD due to polycystic kidney disease
and depression [2]. Similarly, Wolfgang Amadeus Mozart was
also thought to have had CKD [3] and depression [4]. A list of
‘Famous People Who Have Died from Kidney Disease’ [5]
includes many who suffered from both CKD and depression or
other signs of mental illness.
Is this a coincidence or actually evidence of a link between
kidney disease and brain dysfunction? This is not merely an ac-
ademic question because all forms of mental illness can seri-
ously impair an individual’s quality of life, and are frequently
associated with progression of diseases and premature mortal-
ity, so it is worth the effort of trying to answer it.
Europe and much of the industrialized countries are
experiencing growing numbers of patients with CKD within
their ageing populations [6]. CKD is complex and potentially
fatal: (i) all organs are affected, sooner or later; (ii) the balance
of plasma volume, electrolytes, acid–base and minerals,
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metabolites, hormones and proteins is disturbed; and (iii)
patients often need a multidisciplinary team approach manag-
ing complex comorbidities, drug regimens and special diets.
Although the prognosis of patients with CKD remains poor,
their increasing life expectancy has shifted medical attention
from life-threatening emergencies to long-term complications
and sequelae, and how to improve quality of life [7]. Indeed,
kidney failure has detrimental effects on health-related quality
of life (HRQoL), reaching levels similar to those seen in patients
with metastatic cancer [8]. This might be due to psychological
factors, both kidney disease and cancer being chronic diseases
with a bad prognosis. However, although the effect of CKD on
quality of life is more evident in advanced stages (stage G4þ)
and in older patients [9, 10], a large study has shown a signifi-
cant decrease in HRQoL as early as CKD stage G2 [11].
Notably, neurological and cognitive impairments [12], and
depression [13] are among the most debilitating consequences
of CKD contributing to the significantly reduced HRQoL [14].
MILD COGNITIVE IMPAIRMENT IN CKD
Historical perspective
The recognition of the association of uraemia with brain
dysfunction goes back to the 1930s when Toulouse, Marchand
and Courtois postulated ‘a specific disease entity with azotemia
as one of the most characteristic symptoms: azotemic acute psy-
chotic encephalitis’ [15]. The disease was subsequently renamed
‘uraemic encephalitis’ or ‘uraemic encephalopathy’ [16], includ-
ing ‘the full spectrum of organic brain syndromes, progressing
frommild impairment of intellect to coma’ [17].
At the same time, post-mortem studies in humans, particu-
larly by Olsen [18], and in animal models were devoted to iden-
tifying the underlying brain abnormalities. The major
anatomical changes observed in uraemia were white matter ab-
normalities, brain atrophy and neuronal degeneration [17];
functional alterations were also observed, consisting of changes
in the permeability of the blood–brain barrier with resultant
brain oedema [19], and altered content of neurotransmitters
[20].
Initially, ‘uraemic encephalopathy’ was thought to be revers-
ible by haemodialysis based on the assumption that it was
caused by retained small molecule toxins. Already in 1967
Fishman and Raskin, however, predicted that ‘it is very likely
that no single toxic compound will be identified’ [17], meaning
that brain alterations might be due to multiple individual and
additive causes.
At the end of the 1960s, another neurological state, caused
by aggressive dialysis in advanced uraemic states, was identified
and called (dialysis) ‘disequilibrium syndrome’ [21]. In the
1970s, a peculiar form of dementia associated with chronic dial-
ysis, called ‘dialysis dementia’, was also described and attributed
to trace metals, most likely aluminium [22].
In the 1990s, significant improvements in dialysis methods
and regimens were achieved, and the occurrence of advanced,
untreated uraemic states was significantly reduced. The inci-
dence of ‘disequilibrium syndrome’, ‘dialysis dementia’ and
‘uraemic encephalopathy’ was beginning to decline and
attention shifted to the potentially beneficial brain effects of
epoetin and growth hormone in CKD [23]; probably due to the
wider availability of these new therapeutic options.
Furthermore, as dialysis outcomes were steadily optimized,
in part due to working groups such as DOQI in the 1980–
90s, the meaning of the term ‘uraemia’ was changing from
the terminal stages of body intoxication to the ‘residual syn-
drome’ defined by Depner [24] as the effects were not cor-
rected by dialysis and possibly the result of other retained
metabolic waste products.
With the success of the KDOQI classification of CKD in
2002, the term uraemia was confined to the terminal condition
of (often more acute) intoxication. Dialytic techniques then fo-
cused on the removal of medium-sized molecules, such as b-2
microglobulin, responsible for amyloid deposition in tissues, in-
cluding the brain [25]. Unfortunately, no data are available yet
on the prevention of mild cognitive impairment (MCI) using
these new techniques.
At the same time, milder neurological disease states, and
more specifically cognitive decline in earlier CKD stages, came
into focus. Thus, current studies no longer consider ‘uraemic
encephalopathy’ as such, but are more commonly concerned
with the recognition and nature of cognitive decline in CKD.
Cognitive assessment
Cognitive decline is one of the behavioural manifestations of
brain damage in CKD. Other manifestations of brain dysfunc-
tion are sleep disturbances and depression, which represent a
wide topic that is not covered in the present review.
Patients with CKD show high prevalence of depression that
can often appear as a reversible form of cognitive impairment,
hence it is often called ‘pseudodementia’ or ‘functional demen-
tia’ [26]. The identification of this form is difficult and the
reader should refer to more specialized reviews (see e.g. [27]).
Depression might itself be an effect of cognitive impairment.
Prototypical forms of dementia such as Alzheimer’s disease and
dementia with Lewy bodies, are, in fact, accompanied by a high
prevalence of depression [28]. Furthermore, cognitive impair-
ment usually persists after significant improvements in depres-
sive symptoms (see e.g. [29]). Therefore, the coexistence of
depression andMCI-CKDmight be part of a more general phe-
nomenon, rather the presence of two different nosological
entities.
Similarly, the association of peripheral neuropathy and cog-
nitive impairment in patients with CKD can be observed in
other conditions such as diabetes [30], vitamin B12 deficiency
[31] and amyloidosis [32]. These associations wait to be better
understood in the population of patients with CKD.
The cognitive decline can manifest with a continuum from
mild involvement, or MCI, up to clinically relevant dementia,
when interference with daily life and independency is present.
Being a prodromal stage, MCI should be identified and studied
in CKD before irreversible damage is present. MCI is character-
ized by mild impairment in several key cognitive domains, that
is, executive functions of memory (learning and attention),
problem solving (processing) and self-control (emotion—
depression).
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These domains can be captured by screening tests, for exam-
ple, the Montreal Cognitive Assessment (MoCA), and neuro-
psychological tests, often leading to the diagnosis of MCI
(Figure 1). The MoCA has been specifically designed for the
detection of MCI, with a sensitivity of 80–100% and specificity
of 50–76% using a cut-point of 25/26 [33].
Routine screening for MCI in CKD patients is not yet rec-
ommended, notwithstanding the high prevalence of the condi-
tion. This could be partially explained by the lack of
intervention strategies once the condition has been recognized.
However, the nephrologist should suspect cognitive impair-
ment when the patient (or the caregiver) reports forgetfulness/
confusion about medications, appointments or inappropriate
calls, or when the patient reports depression or altered sleep
patterns, and when the patient is not able to answer questions
without the family member/caregiver, and in all cases of history
of stroke or unexplained falls.
MCI is a transitional stage, preceding clinical dementia, with
cognitive impairment exceeding normal ageing and age-
associated decline [34]. The main difference between dementia
and MCI is that in the former the severity of cognitive impair-
ment usually interferes with activities of daily living; however, it
is almost certainly a spectrum with evidence that modifiable
cardiovascular risk factors, physical exercise and cognitive
training can slow progression [35].
Nature of cognitive impairment
In recent years, several clinical studies have concentrated on
the burden of MCI in CKD patients (see e.g. [36–38]). Among
patients with CKD, the prevalence of MCI has been estimated
to be as high as 30% [39] to 63% [40], which is approximately
twice as high as in the age-matched general population. The
stage of CKD is apparently related to the risk of MCI: the lower
the estimated glomerular filtration rate (eGFR) the higher the
risk of MCI (see also Table 1). Notably, discernible cognitive
changes may appear already in early CKD stages [51].
Interestingly, patients with end-stage renal disease (ESRD)
have a similar MCI burden with or without haemodialysis, or
peritoneal dialysis (Table 1). This is surprising because recent
data show that haemodialysis modifies cerebral blood flow as a
function of ultrafiltration volume [52]. However, after
12months, this brain haemodynamic effect correlates with a
better performance with the MoCA test for MCI [53]. This ob-
servation is also supported by the improvement of the cognitive
functions after the start of dialysis, possibly with better results
using peritoneal dialysis compared with haemodialysis [54].
Therefore, the decline of cerebral blood flow observed during
haemodialysis may not contribute toMCI.
This might be interpreted as the presence of toxins not elimi-
nated by the dialysis process, or the deficit of (as yet unknown)
neuroprotective substances produced by the kidney that have
not been directly replaced yet.
Much effort has been devoted to identifying specific risk fac-
tors for MCI in patients with CKD. To address this problem,
investigators had to control several risk factors known for MCI
in the general population, such as age, a family history for MCI,
the education level, exposure to environmental chemicals,
physical inactivity, diabetes, heart disease, stroke or other past
brain injuries, male gender, hypertension, smoking, weight and
hypercholesterolaemia [55]. Genetic susceptibility towards
MCI, such as apoE genotype, is likely to play the same role in
the general population and in CKD patients [56]. Nephrologists
can easily recognize that many of these factors accompany
CKD itself.
However, when these confounders are taken into consider-
ation, other CKD-specific risk factors can be identified such as
albuminuria [57], normalized brain tissue volume, haemoglo-
bin levels, glycaemia, serum parathyroid hormone and uric acid
levels [58]. Another CKD-specific risk factor for MCI is the fre-
quent presence of electrolyte disorders. Among these, hypona-
traemia is relatively frequent in ESRD and has been associated
with lower scores for tests of MCI [59]. However, it should be
underlined that hyponatraemia is also a risk factor for MCI in
non-CKD patients [60]. Other possible CKD-related factors for
MCI are the duration of CKD, poor nutrition/protein energy
wasting, neuro-psychological aspects, functional impairment,
anaemia, acidosis, disturbed sleep and polypharmacy [61], al-
though they are difficult to assess and have not been explored in
any detail. The relative contribution of these and other factors
and the still poorly understood underlying mechanisms remain
major obstacles to prevention and treatment.
In the population of CKD patients under dialysis, additional
risk factors for MCI are related to the process and adequacy of
renal replacement therapies. Specifically, risk factors for MCI
are the total number of dialysis-related hypotension events [62]
and, counterintuitively, a high equilibrated Kt/V>1.2 [39].
With respect to the dialysis modality, the risk for MCI is
lower when the patients are placed on peritoneal dialysis or a
central venous catheter is avoided [63]. However, the effects of
different dialysis modalities on MCI could be spurious because
of a selection bias of the patients, since randomization is usually
not feasible.
Kidney transplantation appears to reduce MCI (see Table 1),
and this change is likely to be stable at 1 and 2 years after trans-
plantation, suggesting the potential for some reversibility [64].
The reasons for this effect are still unclear. An attractive and
untested hypothesis is that the kidney produces neurotrophic
factors that are necessary for normal cognition in the long term.
However, several other hypotheses are equally possible at this
stage.
Recent data suggest that a specific mechanism of brain im-
pairment in CKD may be linked to chronic inflammation [13],
altered levels of serum uric acid, parathyroid hormone levels,
low glycaemia [58] and of neuropeptide Y (NPY), a sympathetic
neurotransmitter thought to be involved in cognition and
memory [65] and dysregulated in CKD [50]. The relevance of
NPY is partially supported by the presence of autonomic dys-
function in CKD [66]. MCI itself is a risk factor for mortality, as
already mentioned, and contributes significantly to the poorer
quality of life of CKD patients [61].
Is MCI-CKD a new and recognized clinical entity?
MCI represents highly heterogeneous phenotypes with dif-
ferent underlying aetiologies (Figure 2). The MCI diagnosis
12 D. Viggiano et al.
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relies (at least in part) on questionnaires testing multidimen-
sional abilities of the patient (arithmetic, basic motor skills,
time and place perception, repeating word list, language use
and comprehension). This multidimensional testing procedure
may lead to the grouping of different disease entities under a
single heading of ‘MCI’.
Indeed, the concept of MCI was developed in the field of de-
mentia, particularly for the population at risk of Alzheimer’s
disease. Only much later, this concept has been applied to the
study of cognitive changes in CKD.
Therefore, it is very instructive to use the large body of neu-
rophysiological and imaging data available from patients with
MCI in the general population and to compare these with the
MCI pattern found in the population of CKD patients. To dis-
tinguish these two populations, we will use the term MCI-GP
when referring to the general population and MCI-CKD when
referring to the CKD population.
A large body of data comes from electroencephalographic
(EEG) recordings. The first EEG studies in CKD were per-
formed in the early 1960s [67, 68]. In a recent study comparing
EEGs from MCI-GP with MCI-CKD, subtle differences
emerged between the two populations: MCI-GP was character-
ized by alterations in the alpha rhythm (8–13Hz), whereas
MCI-CKD was characterized by alterations in the delta fre-
quencies (<4 Hz) [69]. The interpretation of these differences is
speculative: the alpha rhythm in the occipital cortex is normally
present during quiet wakefulness and is thought to represent
sensory information processing, modulated by the cholinergic
input to the cortex. Conversely, the delta rhythm is normally
present during sleep and is thought to derive from abnormal in-
teraction between the thalamus and the cortex. Therefore,
MCI-GPmight be characterized by an altered cholinergic input,
whereas in MCI-CKD an altered cortico-thalamic connectivity
might prevail, although this is entirely speculative.
Judgment
Motivation
Language  
CKD
Personality
changes
Completion of
routine tasks
Mood or
behavior
Mini Mental State
Examination
(MMSE)
Neuropsychological tests
Cognitive domains
Addenbrooke’s
Cognitive Examination
(ACE-R)
Mini-cognitive
assessment instrument
(MINI-Cog)
Montreal Cognitive
Assessment (MoCA)
Score:
>26 = normal
<26 = MCI
Executive function/
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Concentration-attention/
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FIGURE 1: Clinical testing of MCI in CKD patients. The diagnosis of MCI requires normal execution of routine tasks, and without interfer-
ence with daily activity. Neuropsychological testing can be useful for screening although a full diagnosis requires further documentation. The
neuropsychological tests usually evaluate multiple cognitive domains that are summarized in a single score. The MoCA has been validated as
having better sensitivity then Mini Mental State Examination for MCI screening.
Table 1. Prevalence of MCI and dementia in different populations
Population Prevalence of MCI (%) Prevalence of dementia (%) References
Healthy subjects 7–26 13 [41–43]
Early CKD (Stage 3) 14 Unknown [39, 44]
Late CKD (Stage 4 and 5) 16–38 Unknown [45, 46]
Haemodialysis 26–60 15–36 [47, 48, 51]
Peritoneal dialysis 35 3.9–31 [42, 49, 51]
Transplantation (Only studies comparing pre–post transplant scores) 22 [50]
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Imaging data based on magnetic resonance imaging (MRI)
yielded results concerning the brain alterations in MCI-CKD.
Unfortunately, no study directly compared patients with MCI-
GP andMCI-CKD usingMRI. Morphological data on the brain
in CKD were initially available only on post-mortem samples;
the first imaging study in living patients with CKD, using MRI,
was published in the 1990s and focused on uraemic encepha-
lopathy, the involvement of basal ganglia and its reversibility
with dialysis [70].
Recent data show a reduction in grey matter (particularly in
amygdala, hippocampus) with sparing of white matter in MCI-
GP [71, 72]. Conversely, MCI-CKD presented with mostly
white matter loss (demyelination), particularly in deep white
matter, and reduced grey matter volume (possibly correlated to
the axonal damage following demyelination) [73]. Again, the
interpretation of these morphological differences is speculative,
and toxic effects of uraemic substances cannot be excluded.
An advanced MRI technique called ‘Diffusion Tensor
Imaging’ (DTI) provided more detail of damages in the white
matter. DTI allows the visualization of major brain axonal bun-
dles (such as the corpus callosum) and is therefore also called
‘brain tractography’. No direct comparison between MCI-GP
and MCI-CKD exists, and so we must rely on separate reports.
In MCI-GP, modifications in white matter tracts were found in
right and left frontal lobe, fornix, corpus callosum, right tempo-
ral lobe, hippocampus head, corpus callosum right and forceps
major [74], with lower connectivity at the level of the basal nu-
cleus [75]. Conversely, in MCI-CKD, DTI showed abnormal
myelination in the anterior limb of the internal capsule [76, 77]
and whole-brain microstructural changes [78].
Finally, functional imaging data relying on brain oxygena-
tion levels (fMRI) or positron emission tomography (PET)
scans have been used to characterize brain activity in MCI-GP
and MCI-CKD, but again without direct comparison. The first
PET study of the brain in uraemia was conducted in 2004, again
focusing on the basal ganglia [79]. fMRI data showed similari-
ties in cerebral blood flow in patients with MCI-CKD and those
with affective disorders [80], whereas this finding has not been
observed in patients with MCI-GP.
Additional information on brain architecture/function
comes from animal models. Different animal models of MCI
(without CKD) have been proposed, including aged or hyper-
tensive rodents, and transgenic mice overexpressing Ab at an
early phase before extensive brain deposits [81]. These animals
show various degrees of cortical atrophy and damage to the
cholinergic system [82]. Conversely, animal models of CKD
(subtotal nephrectomy or high adenine diet) with cognitive im-
pairment [56, 83] show altered sleep patterns [84] with normal
neural architecture [85].
The electrophysiological, imaging and animal model data
suggest differences between MCI-GP and MCI-CKD (see
Table 2). These differences are likely to stem from the underly-
ing pathogenesis of cognitive impairment in individuals with
and without CKD. Since MCI-GP is likely to be a clinical entity
distinct from MCI-CKD, the latter should be considered as a
distinct reno-cerebral syndrome. However, formal testing of
this difference has not yet been carried out and further ques-
tions are still open: is gender influencing/modifying the devel-
opment of MCI-CKD, the same way it is known to influence
MCI-GP? Is the CKD stage important? Is the aetiology of CKD
relevant (there is evidence that albuminuria and eGFR are asso-
ciated withMCI)?
Taking an historical standpoint, this reno-cerebral syndrome
differs from ‘uraemic encephalopathy’, because it appears well
before the uraemia and does not improve with dialysis. It might
be (partially) reversible although data on this are still scarce.
Finally, it is a milder neurological phenotype, presumed to be a
very early stage of what may become full-blown clinical demen-
tia. In that respect, it is a potential health and resource-
demanding ‘time bomb’ in the CKD population and urgently
needs to be addressed.
OPEN QUESTIONS AND OPPORTUNITIES
FOR MCI-CKD: IMAGING AND ‘OMICS ’
Although the first description of uraemic encephalopathy was
published some 80 years ago, our understanding of brain dys-
function in CKD, prevention and treatment is still in its infancy.
The pathogenesis MCI-CKD remains in the realm of hypothesis
and its specificity when compared with MCI-GP is based on
limited data. Nevertheless, the problem has gained increasing
attention among nephrologists as shown by a rapidly increasing
number of publications describing neurological and psychologi-
cal changes in CKD patients: the number of published papers
containing the keywords ‘CKD’ and ‘brain’ was only 130 up to
the year 2012, whereas in the years 2013–18 they are 328 (data
from PubMed).
The main advance in our understanding of this syndrome in
the last 80 years has been more of a change in terminology,
from uraemic encephalopathy to (what we call here and today)
Alzheimer’s disease
Depression
Vascular
cognitive
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Fronto-temporal
dementia
Lewy bodies
dementia
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FIGURE 2: MCI subtypes. According to the number of cognitive
domains involved, and the presence of memory impairment, MCI is
further sub-classified, which can partially separate MCI into different
aetiologies.
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MCI-CKD. While this suggests a growing recognition of the
problem of MCI, it also risks failing to take full account of ear-
lier data and published findings.
We will try to summarize what we believe are the main open
questions worth addressing with the aid of newer technologies:
(i) Does the distinction between MCI-GP and MCI-CKD
really exist or does MCI-CKD only represent an ‘ex-
treme’ or ‘accelerated’ phenotype of MCI-GP?
(ii) What is the contribution of accelerated aging and con-
ventional cardiovascular risk factors to MCI-CKD?
(iii) Do we have firm criteria for the diagnosis of MCI-
CKD?
(iv) What is the ‘natural history’ of MCI-CKD?
(v) Can MCI-CKD be treated, prevented or even reversed?
(vi) Can we properly assess the personal and socio-
economic burden of MCI-CKD?
Why should we be more optimistic today about an advance
in this field? There are at least two reasons: one is the theoretical
approach, and the second is technological.
On the theoretical side, the formal comparison of MCI-CKD
and MCI-GP is urgently needed and is likely to deepen our un-
derstanding of all forms of MCI. At present, the ability to diag-
nose and treat MCI is almost non-existent. Psycho-therapeutic
approaches or physical exercise can be helpful, but are of lim-
ited efficacy. Newer dialysis techniques (e.g. haemodiafiltration)
in patients withMCI-CKD represent an opportunity to evaluate
these potential therapeutic approaches. Furthermore, most
studies have been focused on the association of eGFR and/or al-
buminuria and MCI, but it is plausible that other measures of
kidney function could be useful in understanding the kidney–
brain link [86]. Moreover, the axis involving sympathetic-para-
sympathetic imbalance and inflammation in CKDwarrants fur-
ther investigation.
On the technological side, new high-throughput tools have
become available that may provide new information on the
early identification and pathogenesis of MCI-CKD. These tech-
niques promise to unravel (novel) (neuro)toxins and to system-
atically verify their neurotoxic potential.
So far, fMRI and brain tractography have not been used sys-
tematically in this field, particularly to compare MCI-CKD and
MCI-GP. The ability of these techniques to combine morpho-
logical and functional imaging of the human brain in vivo
with neuro-psychological testing is a unique opportunity.
Furthermore, new transgenic animal models are now available
that allow studying brain activity at the single neuron level
in vivo: transgenic animals with neurons expressing proteins
that are constitutively fluorescent or that change their fluores-
cence with activity to localize and define particular neuronal
populations, and also neurons that can be selectively activated
using laser pulses (optogenetics). New technologies such as
two-photon microscopy and super-resolution microscopy
should allow us to overcome some of the major limitations of
previous imaging techniques. The ‘Clarity’ method can facilitate
an unprecedented ability to investigate the 3D location of neu-
rons in great detail. Robotic systems for drug identification
and well-characterized neuronal cell lines would allow us to
formally and thoroughly test large lists of potential uraemic
(neuro)toxins, as well as new drugs, and their combined effects.
The possibility of deriving stem cells from patients and brain
organoids could represent a new in vitromodel for studying the
pathogenesis and reversibility of MCI.
The widespread availability of ‘omic’ technologies (proteo-
mics, peptidomics, genomics, transcriptomics, metabolomics,
etc.) provides a large amount of data that may predict or explain
the occurrence of MCI and its neurological counterparts.
Finally, new statistical techniques to handle ‘big data’, such as
Systems Genetics [87] and Imaging Genetics [88], network
analysis and the application of artificial intelligence algorithms
promise a new level of understanding.
These new technological and methodological advances
promise the opportunity to gain a new and better understand-
ing of MCI-CKD, as well as MCI-GP. MCI-CKD will become
an increasing problem faced by the nephrology community and
it is therefore essential that we liaise closely with our clinical col-
leagues in neurology, neuro-psychology and radiology, as well
as basic scientists in neuroscience, to address this anticipated
major personal health and socio-economic burden.
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